Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.
Saved in:
| Title: | Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis. |
|---|---|
| Authors: | Cai H; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China., Fang L; Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China., Lin J; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China., Zheng Z; Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2024 Oct 21; Vol. 15, pp. 1476256. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2024.1476256 |
